Last reviewed · How we verify
[F-18]Flornaptitril
Flornaptitril is a beta-2 adrenergic receptor agonist.
Flornaptitril is a beta-2 adrenergic receptor agonist. Used for Atrial fibrillation for stroke prevention.
At a glance
| Generic name | [F-18]Flornaptitril |
|---|---|
| Sponsor | CereMark Pharma, LLC |
| Drug class | beta-2 adrenergic receptor agonist |
| Target | beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Flornaptitril acts as a beta-2 adrenergic receptor agonist, which means it stimulates the beta-2 receptors in the body. This stimulation leads to an increase in heart rate and contractility, making it a potential treatment for conditions such as atrial fibrillation.
Approved indications
- Atrial fibrillation for stroke prevention
Common side effects
- Palpitations
- Tachycardia
- Hypotension
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- [F-18]Flornaptitril CI brief — competitive landscape report
- [F-18]Flornaptitril updates RSS · CI watch RSS
- CereMark Pharma, LLC portfolio CI